ATX-304 (formerly O304) vs SLU-PP-332

ATX-304 (formerly O304) (B-tier) vs SLU-PP-332 (C-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

ATX-304 (formerly O304) · tier B

an investigational oral AMPK activator with one small randomized diabetes trial, a newer obesity pilot, and an animal pharmacokinetic curve that cannot establish a human dosing interval.

the AMPK pharmacology and early human signal are real, but the clinical file is too small and short to establish durable weight loss or long-term safety.

65 participants in the published 28-day randomized trial · half-life human terminal half-life not published; approximately 11 hours shown only as a low-confidence mouse apparent-decline proxy · weight loss

SLU-PP-332 · tier C

SLU-PP-332 is a small-molecule pan-ERR agonist with mouse endurance and metabolic results, ex vivo human myoblast work, no oral bioavailability, and no human administration study.

SLU-PP-332 activates an oxidative exercise-response program and improved specific outcomes in mice. It has not been administered to people in the located record.

0 human administration studies · half-life no numeric human or animal concentration-time curve retained · weight loss

at a glance

• ATX-304 (formerly O304): tier B · 65 participants in the published 28-day randomized trial
• SLU-PP-332: tier C · 0 human administration studies

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.